Related Links
American Nephrology Nurse’s Association
American Society of Nephrology
American Society of Transplantation
Centers for Medicare & Medicaid Services (CMS)
Food and Drug Administration
Forum of ESRD Networks
Hypertension, Dialysis and Clinical Nephrology
Information for Vermont Prescribers of Prescription Drugs (PDF)
Kidney and Urology Foundation
Kidney Transplant Dialysis Association
Life Options rehabilitation Program
National Institute of Diabetes and Digestive and Kidney Diseases
National Kidney Foundation
National Renal Administrators Association
National Transplant Assistance Fund
Nephrology Linx
Nephron Information Center
Physicians Weekly
Polycystic Kidney Foundation
Renal Net
Renal Physicians Association
Renal Web
Transweb
US Renal Data System
Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis. Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction. Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery. Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation. Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction. Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel. Patients should be informed to take Renagel with meals and to adhere to their prescribed diets. See Renagel Full Prescribing Information. For more information, please see Full Prescribing Information for Renagel or call Genzyme Medical Information at 1-800-847-0069. | 
Genzyme Corporate
